Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bairui granules for common cold (wind-heat syndrome)
ChiCTR2200063903Phase 4Not yet recruiting
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Bairui granules in nasopharyngitis (2 arms), sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoint: Common cold symptom resolution rate after 3 days of treatment. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
Bairui granules
03
Conditions
nasopharyngitis
Beyond the preview
Go deeper on ChiCTR2200063903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063903.